Kurt J. Hilzinger - Feb 22, 2022 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
Director
Signature
/s/ Lawrence A. Kenyon, Attorney-in-Fact
Stock symbol
OTLK
Transactions as of
Feb 22, 2022
Transactions value $
$256,970
Form type
4
Date filed
2/23/2022, 04:42 PM
Previous filing
Jan 4, 2022
Next filing
Feb 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OTLK Common Stock Purchase $142K +95.6K +413.54% $1.49 119K Feb 22, 2022 Direct F1, F2
transaction OTLK Common Stock Purchase $115K +79.5K +67% $1.44 198K Feb 23, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.46 - $1.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
F2 Reflects a one-for-eight reverse stock split effected by the Issuer on March 15, 2019.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.41 - $1.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.